Nanoencapsulated ANP-801

ANP's Nanoencapsulation platform technology has shown promising pre-clinical results for our next generation immune-oncology (I/O) drug, NanoANP-801, a novel immune system modulator - poised to capture a large share of the non-responsive PD-1/PD-L1 immune checkpoint blocker (ICB) market valued at more than $24B.